Latest filing published 25 Jun 2024 for Mirum Pharmaceuticals, Inc., €84k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Pamela Vig (senior executive) discloses dealings in Mirum Pharmaceuticals, Inc. to SEC (Form 4). The record holds 15 filings, for trades running from 10 May 2021 to 24 June 2024.
On the market, this insider has only sold: 4 sales, €125k in total. Other entries cover 10 share grants and 1 option exercise. In 2024 alone, the filings show no purchases and 3 sales.
The newest entry dates from 25 June 2024: an option exercise of €84k, in Mirum Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations